BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 35680734)

  • 1. Local and systemic therapy in breast cancer patients with central nervous system metastases.
    Wellerdieck NEA; Wessels P; Los M; Sonke GS; Tromp E; Brandsma D
    Breast Cancer Res Treat; 2022 Jul; 194(2):365-384. PubMed ID: 35680734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Factors and Survival According to Tumor Subtype in Women With Breast Cancer Brain Metastases.
    Lopes S; Vieira I; Abreu M; Pousa I; Ferreira A; Sousa S; Pereira D
    Curr Probl Cancer; 2022 Dec; 46(6):100866. PubMed ID: 36179388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breast cancer patients with brain metastases or leptomeningeal disease: 10-year results of a national cohort with validation of prognostic indexes.
    Znidaric T; Gugic J; Marinko T; Gojkovic Horvat A; Paulin Kosir MS; Golo D; Ivanetic Pantar M; Ratosa I
    Breast J; 2019 Nov; 25(6):1117-1125. PubMed ID: 31286623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Breast cancer brain metastases: clinical and prognostic characteristics of different biological subtypes].
    Zhang T; Li Q; Xu B; Zhang P; Yuan P; Ma F; Wang J; Fan Y
    Zhonghua Zhong Liu Za Zhi; 2014 Sep; 36(9):697-702. PubMed ID: 25564062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of T-DM1 in Her2-positive breast cancer brain metastases.
    Bartsch R; Berghoff AS; Vogl U; Rudas M; Bergen E; Dubsky P; Dieckmann K; Pinker K; Bago-Horvath Z; Galid A; Oehler L; Zielinski CC; Gnant M; Steger GG; Preusser M
    Clin Exp Metastasis; 2015 Oct; 32(7):729-37. PubMed ID: 26303828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of human epidermal growth factor receptor 2 status and systemic therapy in breast cancer with brain metastases treated with radiotherapy.
    Tsuruoka S; Kataoka M; Uwatsu K; Makita K; Tsuruoka K; Takata N; Ishikawa H; Hamamoto Y; Mochizuki T; Kido T
    Asia Pac J Clin Oncol; 2023 Jun; 19(3):347-354. PubMed ID: 36281655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics of patients with brain metastases from human epidermal growth factor receptor 2-positive breast cancer: subanalysis of Brain Metastases in Breast Cancer Registry.
    Laakmann E; Witzel I; Neunhöffer T; Park-Simon TW; Weide R; Riecke K; Polasik A; Schmidt M; Puppe J; Mundhenke C; Lübbe K; Hesse T; Thill M; Zahm DM; Denkert C; Fehm T; Nekljudova V; Rey J; Loibl S; Müller V
    ESMO Open; 2022 Jun; 7(3):100495. PubMed ID: 35653983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leptomeningeal metastases from breast cancer: intrinsic subtypes may affect unique clinical manifestations.
    Lee S; Ahn HK; Park YH; Nam DH; Lee JI; Park W; Choi DH; Huh SJ; Park KT; Ahn JS; Im YH
    Breast Cancer Res Treat; 2011 Oct; 129(3):809-17. PubMed ID: 21785952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leptomeningeal Metastasis in ER + HER2- Advanced Breast Cancer Patients: A Review of the Cases in a Single Institute Over a 15-year Period.
    Watanabe J; Mitsuya K; Nakamoto S; Harada H; Deguchi S; Hayashi N; Nakasu Y
    Breast Cancer Res Treat; 2021 Aug; 189(1):225-236. PubMed ID: 33966182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy.
    Park S; Lee MH; Seong M; Kim ST; Kang JH; Cho BC; Lee KH; Cho EK; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Ann Oncol; 2020 Oct; 31(10):1397-1404. PubMed ID: 32634610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic factors of brain metastases from breast cancer: impact of targeted therapies.
    Braccini AL; Azria D; Thezenas S; Romieu G; Ferrero JM; Jacot W
    Breast; 2013 Oct; 22(5):993-8. PubMed ID: 23831232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biological subtypes and survival outcomes in breast cancer patients with brain metastases (study of the Anatolian Society of Medical Oncology).
    Kaplan MA; Isikdogan A; Koca D; Kucukoner M; Gumusay O; Yildiz R; Dayan A; Demir L; Geredeli C; Kocer M; Arslan UY; Inal A; Unal OU; Mert AG; Bilici M; Ozkan M; Elkiran ET; Yaman S; Durnalı AG; Suner A; Alici S; Tarhan MO; Boruban C; Urakci Z; Buyukberber S
    Oncology; 2012; 83(3):141-50. PubMed ID: 22814315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Neratinib Plus Capecitabine in the Subgroup of Patients with Central Nervous System Involvement from the NALA Trial.
    Hurvitz SA; Saura C; Oliveira M; Trudeau ME; Moy B; Delaloge S; Gradishar W; Kim SB; Haley B; Ryvo L; Dai MS; Milovanov V; Alarcón J; Kalmadi S; Cronemberger E; Souza C; Landeiro L; Bose R; Bebchuk J; Kabbinavar F; Bryce R; Keyvanjah K; Brufsky AM
    Oncologist; 2021 Aug; 26(8):e1327-e1338. PubMed ID: 34028126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in the Management of Central Nervous System Metastases from Breast Cancer.
    Avila J; Leone JP
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal management of brain metastases from breast cancer. Issues and considerations.
    Bartsch R; Berghoff AS; Preusser M
    CNS Drugs; 2013 Feb; 27(2):121-34. PubMed ID: 23239265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breast cancer brain metastases - A 12 year review of treatment outcomes.
    De Ieso PB; Schick U; Rosenfelder N; Mohammed K; Ross GM
    Breast; 2015 Aug; 24(4):426-33. PubMed ID: 25881974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The anti-tumor efficiency of low-dose apatinib-based chemotherapy in pretreated HER2-negative breast cancer with brain metastases.
    Chen X; Bai X; Xie X; Huang J; Chen L; Song L; Lan X; Zhang Q; Guo J; Du C
    Ann Med; 2023 Dec; 55(1):2218647. PubMed ID: 37260331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer.
    Larsen PB; Kümler I; Nielsen DL
    Cancer Treat Rev; 2013 Nov; 39(7):720-7. PubMed ID: 23481218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metastatic breast cancer subtypes and central nervous system metastases.
    Aversa C; Rossi V; Geuna E; Martinello R; Milani A; Redana S; Valabrega G; Aglietta M; Montemurro F
    Breast; 2014 Oct; 23(5):623-8. PubMed ID: 24993072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Central nervous system metastases in breast cancer: the impact of age on patterns of development and outcome.
    Ben-Zion Berliner M; Yerushalmi R; Lavie I; Benouaich-Amiel A; Tsoref D; Hendler D; Goldvaser H; Sarfaty M; Rotem O; Ulitsky O; Siegal T; Neiman V; Yust-Katz S
    Breast Cancer Res Treat; 2021 Jan; 185(2):423-432. PubMed ID: 33037977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.